Sweden, the first country to introduce legal gender reassignment, has begun restricting gender reassignment hormone treatments for minors, as it, like many Western countries, grapples with the highly-sensitive issue.
With the number of diagnoses soaring, the medical community faces the dilemma of weighing precaution against the risks associated with not offering treatment to those suffering from “gender dysphoria.”
Sweden decided in February 2022 to halt hormone therapy for minors except in very rare cases, and in December, the National Board of Health and Welfare said mastectomies for teenage girls wanting to transition should be limited to a research setting.
“The uncertain state of knowledge calls for caution,” Board department head Thomas Linden said in a statement in December.
So-called puberty blockers have been used in young teens contemplating gender transition to delay the onset of unwanted physical changes.
Like many other countries, Sweden has seen a sharp rise in cases of gender dysphoria, a condition where a person may experience distress as a result of a mismatch between their biological sex and the gender they identify as.
According to the Board of Health and Welfare, approximately 8,900 people were diagnosed with gender dysphoria in Sweden between 1998 and 2021, in a country of around 10 million.
In 2021 alone, about 820 new cases were registered.
The trend is particularly visible among 13- to 17-year-olds born female, with an increase of 1,500 percent since 2008.
“It used to be a male phenomenon and now there is a strong female over-representation,” psychiatrist Mikael Landen, chief physician at Sahlgrenska University Hospital in Gothenburg, told AFP.
Landen, who contributed to the scientific study on which the Board of Health based its decision, said the reasons for this increase remain largely a “mystery.”
“Tolerance has been high in Sweden for at least the last 25 years, so you can’t say it has changed,” he said when asked if it was simply a result of a more accepting society.
The profile of those diagnosed is often complex, according to Linden, as gender dysphoria often occurs in those also suffering from other diagnoses, such as attention deficit and eating disorders or autism.
In May 2021 – before the Swedish authorities’ decision to restrict gender reassignment hormone treatments – the prestigious Karolinska Hospital in Stockholm chose to restrict such hormone treatments to research projects only.
Other countries are weighing the same questions.
Neighboring Finland took a similar decision in 2020, while France has called for “the utmost reserve” on hormone treatments for young people.
The UK meanwhile saw a high-profile court case in 2020.
Keira Bell, who regretted her transition from female to male, filed a complaint against the public body responsible for gender dysphoria treatments, claiming she had been too young at age 16 to consent to the treatments.
She ultimately lost her case.
Sweden’s recent rollback is all the more notable as it was first in the world to authorize legal gender transition in 1972, paving the way for sex reassignment surgery to be covered by its universal healthcare system.
Rights groups have expressed concern.
Elias Fjellander, president of the youth branch of RFSL, the country’s main organisation championing LGBTQ rights, says Sweden’s decision risks leading to increased suffering.
“These people might need more care and invasive procedures in the future, because the decision could not be made earlier, even though the medical need was there,” he said.
Twenty-year-old Antonia Lindholm, a trans woman who began her transition as a teenager, agreed.
“I think hormones save a lot of people,” she told AFP.
“If I were 13 today, I wouldn’t have a chance” of getting this treatment, Lindholm added.
